These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 29959813)

  • 1. Multiple sclerosis: severe exacerbation after stopping disease-modifying drugs.
    Członkowska A; Mirowska-Guzel D
    Eur J Neurol; 2018 Oct; 25(10):1199-1200. PubMed ID: 29959813
    [No Abstract]   [Full Text] [Related]  

  • 2. Disease Exacerbation after the Cessation of Fingolimod Treatment in Japanese Patients with Multiple Sclerosis.
    Sato K; Niino M; Kawashima A; Yamada M; Miyazaki Y; Fukazawa T
    Intern Med; 2018 Sep; 57(18):2647-2655. PubMed ID: 29709955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unexpected high multiple sclerosis activity after switching from fingolimod to alemtuzumab.
    Bernard-Valnet R; Pignolet B; Biotti D; Ciron J; Lafontan JF; Dumas H; Bonneville F; Brassat D
    Mult Scler Relat Disord; 2018 Oct; 25():216-218. PubMed ID: 30114625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.
    Członkowska A; Smoliński Ł; Litwin T
    Neurol Neurochir Pol; 2017; 51(2):156-162. PubMed ID: 28209440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The 'Field Hypothesis': rebound activity after stopping disease-modifying therapies.
    Giovannoni G; Hawkes C; Waubant E; Lublin F
    Mult Scler Relat Disord; 2017 Jul; 15():A1-A2. PubMed ID: 28641776
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe rebound after withdrawal of fingolimod treatment in patients with multiple sclerosis.
    Gündüz T; Kürtüncü M; Eraksoy M
    Mult Scler Relat Disord; 2017 Jan; 11():1-3. PubMed ID: 28104247
    [No Abstract]   [Full Text] [Related]  

  • 7. Cutaneous cryptococcosis in a patient taking fingolimod for multiple sclerosis: Here come the opportunistic infections?
    Carpenter AF; Goodwin SJ; Bornstein PF; Larson AJ; Markus CK
    Mult Scler; 2017 Feb; 23(2):297-299. PubMed ID: 28165320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.
    Naegelin Y; Rasenack M; Andelova M; Von Felten S; Fischer-Barnicol B; Amann M; Mehling M; Kappos L; Sprenger T; Derfuss T
    Mult Scler Relat Disord; 2018 Oct; 25():14-20. PubMed ID: 30014876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation.
    Andrade C
    JAMA Neurol; 2016 Nov; 73(11):1375-1376. PubMed ID: 27669463
    [No Abstract]   [Full Text] [Related]  

  • 10. Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation.
    Merschhemke M; Tomic D; Putzki N
    JAMA Neurol; 2016 Nov; 73(11):1375. PubMed ID: 27669336
    [No Abstract]   [Full Text] [Related]  

  • 11. Rebound Syndrome in Multiple Sclerosis After Fingolimod Cessation-Reply.
    Hatcher SE; Waubant E; Graves JS
    JAMA Neurol; 2016 Nov; 73(11):1376. PubMed ID: 27669526
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.
    Fox RJ; Chan A; Zhang A; Xiao J; Levison D; Lewin JB; Edwards MR; Marantz JL
    Curr Med Res Opin; 2017 Feb; 33(2):175-183. PubMed ID: 27733070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous anaplastic large cell lymphoma in a multiple sclerosis patient receiving Fingolimod.
    Manouchehri N; Mirmosayyeb O; Badihian S; Shaygannejad V
    Mult Scler Relat Disord; 2018 Jan; 19():121-123. PubMed ID: 29195114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment.
    Hatcher SE; Waubant E; Nourbakhsh B; Crabtree-Hartman E; Graves JS
    JAMA Neurol; 2016 Jul; 73(7):790-4. PubMed ID: 27135594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the cerebral gray matter volume in response to fingolimod therapy in multiple sclerosis: A more analytic view.
    McGee JC; Minagar A
    J Neurol Sci; 2017 Dec; 383():230-231. PubMed ID: 29102163
    [No Abstract]   [Full Text] [Related]  

  • 16. Famous.
    Kim MJ; Bhatti MT; Costello F
    Surv Ophthalmol; 2016; 61(4):512-9. PubMed ID: 26742785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis.
    Thomas K; Proschmann U; Ziemssen T
    Expert Opin Pharmacother; 2017 Oct; 18(15):1649-1660. PubMed ID: 28844164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Visceral leishmaniasis infection in a fingolimod-treated multiple sclerosis patient.
    Artemiadis AK; Nikolaou G; Kolokythopoulos D; Tegos N; Terentiou A; Triantafyllou N; Papanastasiou I
    Mult Scler; 2015 May; 21(6):795-6. PubMed ID: 25432949
    [No Abstract]   [Full Text] [Related]  

  • 19. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report.
    Ueda N; Saida K
    BMC Ophthalmol; 2015 Oct; 15():135. PubMed ID: 26481728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comment on: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis".
    Tsivgoulis G; Palaiodimou L; Katsanos AH; Voumvourakis K; Hadjigeorgiou GM; Heliopoulos I; Karapanayiotides T; Papathanasopoulos P; Kilidireas C; Grigoriadis N
    CNS Drugs; 2019 Mar; 33(3):293-295. PubMed ID: 30806966
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.